This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00463-08v1 52/11/3851    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Holmes, A. R. Articles by Cannon, R. D. PubMed PubMed Citation Articles by Holmes, A. R. Articles by Cannon, R. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2008, p. 3851-3862, Vol. 52, No. 11
0066-4804/08/$08.00+0     doi:10.1128/AAC.00463-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

ABC Transporter Cdr1p Contributes More than Cdr2p Does to Fluconazole Efflux in Fluconazole-Resistant Candida albicans Clinical Isolates

Department of Oral Sciences, School of Dentistry, University of Otago, Dunedin, New Zealand,¹ Department of Bioactive Molecules, National Institute of Infectious Diseases, Tokyo, Japan²

Received 7 April 2008/ Returned for modification 25 June 2008/ Accepted 3 August 2008

Fluconazole (FLC) remains the antifungal drug of choice for non-life-threatening Candida infections, but drug-resistant strains have been isolated during long-term therapy with azoles. Drug efflux, mediated by plasma membrane transporters, is a major resistance mechanism, and clinically significant resistance in Candida albicans is accompanied by increased transcription of the genes CDR1 and CDR2, encoding plasma membrane ABC-type transporters Cdr1p and Cdr2p. The relative importance of each transporter protein for efflux-mediated resistance in C. albicans, however, is unknown; neither the relative amounts of each polypeptide in resistant isolates nor their contributions to efflux function have been determined. We have exploited the pump-specific properties of two antibody preparations, and specific pump inhibitors, to determine the relative expression and functions of Cdr1p and Cdr2p in 18 clinical C. albicans isolates. The antibodies and inhibitors were standardized using recombinant Saccharomyces cerevisiae strains that hyper-express either protein in a host strain with a reduced endogenous pump background. In all 18 C. albicans strains, including 13 strains with reduced FLC susceptibilities, Cdr1p was present in greater amounts (2- to 20-fold) than Cdr2p. Compounds that inhibited Cdr1p-mediated function, but had no effect on Cdr2p efflux activity, significantly decreased the resistance to FLC of seven representative C. albicans isolates, whereas three other compounds that inhibited both pumps did not cause increased chemosensitization of these strains to FLC. We conclude that Cdr1p expression makes a greater functional contribution than does Cdr2p to FLC resistance in C. albicans.

Published ahead of print on 18 August 2008.